Novo Nordisk Utilizes Gefion AI Supercomputer for Drug Discovery
Novo Nordisk has entered into a multiyear agreement with DCAI to utilize the Gefion AI supercomputer, as announced in a press release. This collaboration aims to enhance drug discovery and healthcare innovation by harnessing Gefion's advanced computational capabilities.
The agreement allows Novo Nordisk to access Gefion's NVIDIA DGX SuperPod technology, which is expected to accelerate the development of new therapies by processing vast datasets. This initiative is part of Novo Nordisk's strategic focus on integrating AI across its value chain.
Gefion, ranked 21st on the Top500 list of supercomputers, will support Novo Nordisk in tackling compute-heavy challenges such as AI-based protein engineering and biological modeling. The partnership also includes collaboration with NVIDIA to develop customized models for early research and discovery.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 22 BioStack Raises $9.5 Million for Medical AI Data Network Oct 22 Warp Sciences Raises $215 Million to Automate Drug Discovery Labs Oct 22 FDA Clears RIVANNA BoneEnhance Software for Accuro XV Oct 22 Tufts Medicine Uses Humata Health to Automate Prior Authorization Oct 22 HHS Plans Sole Source Claude Contract With AnthropicLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
NVIDIA Debuts RFD4-Proteina and Expands Radiotherapy Work
Genedata Adds NVIDIA RFD4-Proteina to Biologics Discovery Workflows
Inovia Bio Launches Falcon for Drug Development Workflows
Hansa Biopharma Partners With Cradle on AI Protein Design
NVIDIA Brings DSX Power and Cooling Controls to European AI Factories
Daily AI Brief: the AI news that matters, in your inbox.